5 Citations (Scopus)

Abstract

Corticosteroids have been used in the therapy for castration-resistant prostate cancer (CRPC) for decades, both as monotherapy and in combination with additional agents. In this article the authors report the results of a phase II trial of dexamethasone versus prednisolone as monotherapy for CRPC. The study suggests improved PSA and radiographic response rates as well as improved time to PSA progression for dexamethasone over prednisolone therapy; however the differences only trend toward statistical significance. Nonetheless, in light of these data, when treating patients with corticosteroid monotherapy for CRPC it may be prudent to consider using daily dexamethasone over prednisone/prednisolone.

Original languageEnglish (US)
Pages (from-to)207-209
Number of pages3
JournalCancer Biology and Therapy
Volume16
Issue number2
DOIs
StatePublished - Feb 1 2015

Fingerprint

Castration
Prednisolone
Dexamethasone
Prostatic Neoplasms
Adrenal Cortex Hormones
Prednisone
Therapeutics

All Science Journal Classification (ASJC) codes

  • Molecular Medicine
  • Oncology
  • Pharmacology
  • Cancer Research

Cite this

@article{fa93f21430b54b44b235373e274ef5cf,
title = "Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer",
abstract = "Corticosteroids have been used in the therapy for castration-resistant prostate cancer (CRPC) for decades, both as monotherapy and in combination with additional agents. In this article the authors report the results of a phase II trial of dexamethasone versus prednisolone as monotherapy for CRPC. The study suggests improved PSA and radiographic response rates as well as improved time to PSA progression for dexamethasone over prednisolone therapy; however the differences only trend toward statistical significance. Nonetheless, in light of these data, when treating patients with corticosteroid monotherapy for CRPC it may be prudent to consider using daily dexamethasone over prednisone/prednisolone.",
author = "Sheldon Holder and Joseph Drabick and Junjia Zhu and Monika Joshi",
year = "2015",
month = "2",
day = "1",
doi = "10.1080/15384047.2014.1002687",
language = "English (US)",
volume = "16",
pages = "207--209",
journal = "Cancer Biology and Therapy",
issn = "1538-4047",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - Dexamethasone may be the most efficacious corticosteroid for use as monotherapy in castration-resistant prostate cancer

AU - Holder, Sheldon

AU - Drabick, Joseph

AU - Zhu, Junjia

AU - Joshi, Monika

PY - 2015/2/1

Y1 - 2015/2/1

N2 - Corticosteroids have been used in the therapy for castration-resistant prostate cancer (CRPC) for decades, both as monotherapy and in combination with additional agents. In this article the authors report the results of a phase II trial of dexamethasone versus prednisolone as monotherapy for CRPC. The study suggests improved PSA and radiographic response rates as well as improved time to PSA progression for dexamethasone over prednisolone therapy; however the differences only trend toward statistical significance. Nonetheless, in light of these data, when treating patients with corticosteroid monotherapy for CRPC it may be prudent to consider using daily dexamethasone over prednisone/prednisolone.

AB - Corticosteroids have been used in the therapy for castration-resistant prostate cancer (CRPC) for decades, both as monotherapy and in combination with additional agents. In this article the authors report the results of a phase II trial of dexamethasone versus prednisolone as monotherapy for CRPC. The study suggests improved PSA and radiographic response rates as well as improved time to PSA progression for dexamethasone over prednisolone therapy; however the differences only trend toward statistical significance. Nonetheless, in light of these data, when treating patients with corticosteroid monotherapy for CRPC it may be prudent to consider using daily dexamethasone over prednisone/prednisolone.

UR - http://www.scopus.com/inward/record.url?scp=84924545806&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924545806&partnerID=8YFLogxK

U2 - 10.1080/15384047.2014.1002687

DO - 10.1080/15384047.2014.1002687

M3 - Article

C2 - 25756508

AN - SCOPUS:84924545806

VL - 16

SP - 207

EP - 209

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

SN - 1538-4047

IS - 2

ER -